{"id":"treatment-prevention-for-secondary-cv","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"5-10%","effect":"Musculoskeletal pain"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4802202","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting PCSK9, the drug increases the number of LDL receptors on the liver surface, leading to increased clearance of LDL cholesterol from the bloodstream. This results in a reduction of circulating LDL cholesterol levels, which can help prevent cardiovascular events.","oneSentence":"This drug targets the PCSK9 protein to lower LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:00.068Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Secondary cardiovascular prevention in patients with established cardiovascular disease or atherosclerotic cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT02596126","phase":"PHASE3","title":"Secondary Prevention of Cardiovascular Disease in the Elderly Trial","status":"COMPLETED","sponsor":"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","startDate":"2016-07","conditions":"Myocardial Infarction, Cardiovascular Disease","enrollment":2499}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Antiplatelet agents","Lipid Lowering Agents","Renin-angiotensin-aldosterone system blockers"],"phase":"phase_3","status":"active","brandName":"Treatment Prevention for Secondary CV","genericName":"Treatment Prevention for Secondary CV","companyName":"Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III","companyId":"fundaci-n-centro-nacional-de-investigaciones-cardiovasculares-carlos-iii","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug targets the PCSK9 protein to lower LDL cholesterol levels. Used for Secondary cardiovascular prevention in patients with established cardiovascular disease or atherosclerotic cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}